Patents by Inventor Matthew J Lindon

Matthew J Lindon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridinone dicarboxamide for use as bromodomain inhibitors
    Patent number: 10927080
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: February 23, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Stephen John Atkinson, Helen Elizabeth Aylott, Anthony William James Cooper, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20190359572
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Application
    Filed: August 8, 2019
    Publication date: November 28, 2019
    Inventors: Stephen John ATKINSON, Helen Elizabeth AYLOTT, Anthony William James COOPER, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Thomas George Christopher HAYHOW, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • 2-OXO-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
    Patent number: 10471050
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: November 12, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Pyridinone dicarboxamide for use as bromodomain inhibitors
    Patent number: 10428026
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, Helen Elizabeth Aylott, Anthony William James Cooper, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Pyridinone dicarboxamide for use as bromodomain inhibitors
    Patent number: 10370356
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: August 6, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, David House, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20180282301
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Application
    Filed: September 20, 2016
    Publication date: October 4, 2018
    Inventors: Stephen John ATKINSON, Emmanuel Hubert, Lee Andrew HARRISON, Thomas HAYHOW, David HOUSE, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, IAN David WALL, Robert J. WATSON, James Michael WOOLVEN
  • 2-OXO-1,2-DIHYDROPYRIDINE-3,5-DICARBOXAMIDE COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20180280368
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: October 3, 2016
    Publication date: October 4, 2018
    Inventors: Stephen John ATKINSON, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Thomas George Christopher HAYHOW, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS
    Publication number: 20180258044
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Application
    Filed: August 31, 2016
    Publication date: September 13, 2018
    Inventors: Stephen John ATKINSON, Helen Elizabeth AYLOTT, Anthony William James COOPER, Emmanuel Hubert DEMONT, Lee Andrew HARRISON, Thomas George Christopher HAYHOW, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, Ian David WALL, Robert J. WATSON, James Michael WOOLVEN
  • Tetrahydroquinoline derivatives as bromodomain inhibitors
    Patent number: 10059699
    Abstract: The present invention relates to specific novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy as bromodomain inhibitors.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: August 28, 2018
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, David Jonathan Hirst, Philip G. Humphreys, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Christopher Roland Wellaway
  • TETRAHYDROQUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS
    Publication number: 20170298047
    Abstract: The present invention relates to specific novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy as bromodomain inhibitors.
    Type: Application
    Filed: September 9, 2015
    Publication date: October 19, 2017
    Inventors: Stephen John ATKINSON, David Jonathan HIRST, Philip G. HUMPHREYS, Matthew J. LINDON, Alexander G. PRESTON, Jonathan Thomas SEAL, Christopher Roland WELLAWAY
  • Furopyridines as bromodomain inhibitors
    Patent number: 9670221
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 6, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Dominique Amans, Paul Bamborough, Michael David Barker, Rino Antonio Bit, John Alexander Brown, Matthew Campbell, Neil Stuart Garton, Matthew J. Lindon, Tracy Jane Shipley, Natalie Hope Theodoulou, Christopher Roland Wellaway, Susan Marie Westaway
  • FUROPYRIDINES AS BROMODOMAIN INHIBITORS
    Publication number: 20160016966
    Abstract: The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 21, 2016
    Inventors: Dominique AMANS, Paul BAMBOROUGH, Michael David BARKER, Rino Antonio BIT, John Alexander BROWN, Matthew CAMPBELL, Neil Stuart GARTON, Matthew J. LINDON, Tracy Jane SHIPLEY, Natalie Hope THEODOULOU, Christopher Roland WELLAWAY, Susan Marie WESTAWAY
  • Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists
    Patent number: 7615550
    Abstract: The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: November 10, 2009
    Assignee: Glaxo Group Limited
    Inventors: Thomas Daniel Heightman, Simon Teanby Hodgson, Matthew J Lindon, David Matthew Wilson